πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron UK Patents

Full USPTO pharma patent portfolio for Regeneron UK β€” grant dates, expiration, and drug cross-links.

Patents
837
Expiring ≀24m
26

Quick answer

Regeneron UK has 837 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 26 expire within 24 months β€” use filters for patent-cliff planning.

Page 13 of 18

  1. US 9790273

    Anti-HLA-B*27 antibodies and uses thereof

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9771414

    Human antibodies to ebola virus glycoprotein

    Expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9751921

    Apelin fusion proteins and uses thereof

    Expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9751932

    Anti-big-endothelin-1 (big-ET-1) antibodies and uses thereof

    Expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9724411

    Methods for treating hypercholesterolemia and reducing LDL-C using antibodies to PCSK9

    Expires Mon Aug 03 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9718881

    Anti-Activin A antibodies and uses thereof

    Expires Mon Jul 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9718872

    Human antibodies to middle east respiratory syndromeβ€”coronavirus spike protein

    Expires Mon Jul 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9708386

    Modified chimeric polypeptides with improved pharmacokinetic properties

    Expires Mon Jul 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9700025

    Genetically modified major histocompatibility complex animals

    Expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9700027

    Non-human animals having a humanized signal-regulatory protein gene

    Expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9688764

    Methods of treating breast cancer by administering anti-human prolactin receptor (PRLR) antibodies

    Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9687566

    Low affinity FCGR deficient mice

    Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9675692

    Stabilized formulations containing anti-DLL4 antibodies

    Expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9669069

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9657099

    Anti-glucagon antibodies

    Expires Mon May 18 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9657102

    Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof

    Expires Mon May 18 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9655352

    Humanized M-CSF mice

    Expires Mon May 18 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9650444

    Anti-PDGFR-beta antibodies and uses thereof

    Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9644018

    Antibody modulators of APLNR

    Expires Mon May 04 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9636400

    VEGF specific fusion protein antagonist formulations

    Expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9637535

    IL-33 antagonists and uses thereof

    Expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9592271

    Angiopoietin-based interventions for treating cerebral malaria

    Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9587029

    Human antibodies to the glucagon receptor and methods of use thereof

    Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9580489

    VEGF antagonist formulations suitable for intravitreal administration

    Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9574004

    Methods for treating or preventing asthma by administering an IL-4R antagonist

    Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9556277

    Method of treating a TL1A-associated disease or disorder with human antibodies to TL1A

    Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9554563

    Genetically modified mice and engraftment

    Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9550837

    Therapeutic uses of anti-PCSK9 antibodies

    Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9545451

    Anti-PRLR antibodies and methods for killing PRLR-expressing cells

    Expires Mon Jan 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9546218

    Anti-Tie2 antibodies and uses thereof

    Expires Mon Jan 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9540449

    Anti-PCSK9 antibodies with pH-dependent binding characteristics

    Expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9532555

    Humanized dipeptidyl peptidase IV (DPP4) animals

    Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9533039

    Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies

    Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9522185

    Human antibodies to GFR Ξ±3 and methods of treating pain associated with osteoarthritis or bone cancer

    Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9511140

    Stable VEGF antagonist formulations

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9498529

    Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor

    Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9497945

    Humanized dipeptidyl peptidase IV (DPP4) animals

    Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9475869

    Human antibodies to fel d1 and methods of use thereof

    Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9475875

    Anti-EGFRvIII antibodies and uses thereof

    Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9462794

    Non-human animals having a humanized signal-regulatory protein gene

    Expires Mon Oct 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9453072

    Anti-IL-33 antibodies

    Expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9447173

    Human antibodies to respiratory syncytial virus F protein and methods of use thereof

    Expires Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9416167

    Stable liquid formulations of dimer VEGF antagonists

    Expires Mon Aug 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9409990

    Methods of inhibiting tumor growth by antagonizing IL-6 receptor

    Expires Mon Aug 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9402898

    Stabilized formulations containing anti-Ang2 antibodies

    Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9399674

    Human antibodies to Clostridium difficile toxins

    Expires Mon Jul 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9371383

    Anti-ASIC1 antibodies and uses thereof

    Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9359437

    Antibodies comprising chimeric constant domains

    Expires Mon Jun 02 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron UK have?

837 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron UK patents expire?

26 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.